SCHEMBL4670093

SCHEMBL4670093

Nc1ccc(-n2nnn(CCCCC3CCCCC3)c2=O)cc1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.40
ADRB2 P07550 1/20 0.40
ADRB1 P08588 1/20 0.40
ADRB3 P13945 1/20 0.40
RECQL P46063 2/20 0.39
NFE2L2 Q16236 1/20 0.39
GBA1 P04062 2/20 0.38
CYP19A1 P11511 2/20 0.37
CTSD P07339 1/20 0.35
BACE1 P56817 1/20 0.35
CEL P19835 1/20 0.34
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
HPGD P15428 1/20 0.34
ATM Q13315 1/20 0.34
SIGMAR1 Q99720 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4670626 0.99 ADRB2 (0.40) NPSR1ADRB2ADRB1ADRB3RECQL
SCHEMBL4670059 0.96 ADRB2 (0.42) NPSR1ADRB2ADRB1ADRB3RECQL
SCHEMBL4670052 0.96 ADRB2 (0.38) NPSR1ADRB2ADRB1ADRB3RECQL
SCHEMBL4670041 0.95 ADRB2 (0.42) NPSR1ADRB2ADRB1ADRB3RECQL
Water SCHEMBL4673070 0.94 ADRB2 (0.42) NPSR1ADRB2ADRB1ADRB3RECQL
Water SCHEMBL4672111 0.94 ADRB2 (0.42) NPSR1ADRB2ADRB1ADRB3RECQL
SCHEMBL6301320 0.92 ADRB2 (0.41) NPSR1ADRB2ADRB1ADRB3RECQL
SCHEMBL4677838 0.92 NFE2L2 (0.40) NPSR1ADRB2ADRB1ADRB3RECQL
SCHEMBL4670471 0.91 ADRB2 (0.39) NPSR1ADRB2ADRB1ADRB3RECQL
SCHEMBL4670426 0.88 ADRB2 (0.38) NPSR1ADRB2ADRB1ADRB3RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1054881-B1 NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS BAYER CORP (US) 2008-07-30 EP disclosed
US-6903218-B2 Sulfonamide substituted chroman derivatives BAYER PHARMACEUTICALS CORPORATION (US) 2005-06-07 US disclosed
US-20040072843-A1 Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists LADOUCEUR GAETAN H (US) 2004-04-15 US disclosed
US-20030073839-A1 Compounds useful for preparation of Beta-3 adrenoreceptor agonist BAYER PHARMACEUTICALS CORPORATION 2003-04-17 US disclosed
EP-1054881-A1 NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS Bayer Corporation (US) 2000-11-29 EP disclosed
US-6051586-A HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS BAYER CORPORATION (US) 2000-04-18 US disclosed
WO-1999032475-A1 NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS BAYER CORPORATION (US) 1999-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072843-A1 Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists ADRB3, ADRB2, ADRB1 NPSR1 51/4885ADRB2 2/4885ADRB1 3/4885
US-20030073839-A1 Compounds useful for preparation of Beta-3 adrenoreceptor agonist ADRB3, ADRB2, ADRB1 NPSR1 60/4885ADRB2 2/4885ADRB1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.